期刊
BRITISH JOURNAL OF HAEMATOLOGY
卷 198, 期 6, 页码 983-987出版社
WILEY
DOI: 10.1111/bjh.18281
关键词
adult T-cell leukaemia-lymphoma; elderly patients; first-line treatment; mogamulizumab; transplant-ineligible
类别
资金
- JSPS KAKENHI [21K08374, 21K08420]
- Grants-in-Aid for Scientific Research [21K08420, 21K08374] Funding Source: KAKEN
This retrospective study analyzed the clinical outcomes of 39 transplant-ineligible patients with untreated aggressive ATL. The results showed that first-line Mog-containing treatment can significantly improve overall survival compared to chemotherapy alone, even in elderly patients.
Chemotherapy in combination with mogamulizumab (Mog) was approved in Japan in 2014 for untreated aggressive adult T-cell leukaemia-lymphoma (ATL), but the survival benefit remains unclear. Therefore, we retrospectively analysed clinical outcomes in 39 transplant-ineligible patients with untreated aggressive ATL at Kumamoto University Hospital between 2010 and 2021. The probability of four-year overall survival was 46.3% in the first-line Mog-containing treatment group compared to 20.6% in the chemotherapy-alone group (p = 0.033). Furthermore, this survival benefit was observed even in the elderly. In conclusion, first-line Mog-containing treatment can be a promising strategy for transplant-ineligible patients with ATL, especially in the elderly.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据